NCT01157845
Completed
Phase 3
Use of the BreathID Methacetin Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Patients Awaiting Liver Transplantation
ConditionsCirrhosis
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Cirrhosis
- Sponsor
- Virginia Commonwealth University
- Enrollment
- 165
- Locations
- 4
- Primary Endpoint
- Mortality From Liver Failure
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
The methacetin breath test (MBT) is a non-invasive liver function test which measures the ability of the liver to metabolize a tracer dose of a compound to carbon dioxide, which is exhaled. The study hypothesis is that measurement of the MBT will allow earlier detection of a decline in liver function in patients with cirrhosis who are awaiting liver transplantation.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Mortality From Liver Failure
Time Frame: 1 year
Patient dies of liver-related causes within 1 year of study entry
Secondary Outcomes
- Liver Transplantation(1 year)
Study Sites (4)
Loading locations...
Similar Trials
Terminated
Phase 2
BreathID Multi-center HCV Liver Breath Test StudyHepatitis CNCT00350714Meridian Bioscience, Inc.75
Completed
N/A
Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic DecompensationChronic Liver DiseaseNCT02084160Meridian Bioscience, Inc.579
Unknown
Phase 2
¹³C-Methacetin Breath Test (MBT) Methodology StudyHealthy SubjectsChronic Liver DiseaseCirrhosisNCT01205074Hadassah Medical Organization
Completed
N/A
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14NASH - Nonalcoholic SteatohepatitisCirrhosisPortal HypertensionNCT03439189Meridian Bioscience, Inc.343
Completed
N/A
Assessing Portal Hypertension With Methacetin Breath TestPatients With Compensated Liver CirrhosisNCT02143778Meridian Bioscience, Inc.246